Using in vitro/in vivo preclinical models and genetic/pharmacologic approaches, our previous studies supported the concept that Bcl-xL plays a pivotal role in the modulation of properties strictly related to melanoma progression and in the maintenance of cancer stem cell phenotype [19]. The gene discussed is BCL2L1; the disease is melanoma.